Black Diamond director receives 8,961-share stock grant
Rhea-AI Filing Summary
Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Ali Behbahani received a grant of 8,961 shares of common stock at $1.66 per share. These shares were issued under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy, in which he elected stock instead of cash for annual board service.
After this award, Behbahani directly holds 102,529 shares of common stock. Separately, 4,448,757 shares are reported as indirectly held by New Enterprise Associates 16, L.P., where he is affiliated through general partner entities. He disclaims beneficial ownership of portions of those indirect holdings in which he has no pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 8,961 shares
Net Buy
2 txns
Insider
Behbahani Ali
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 8,961 | $1.66 | $15K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 102,529 shares (Direct);
Common Stock — 4,448,757 shares (Indirect, See Note 3)
Footnotes (3)
- F1. These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
- F2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026.
- F3. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.
Key Figures
Director stock grant: 8,961 shares
Grant reference price: $1.66 per share
Direct holdings after grant: 102,529 shares
+1 more
4 metrics
Director stock grant
8,961 shares
Common Stock grant for annual non-employee director services
Grant reference price
$1.66 per share
Closing market price on June 18, 2026
Direct holdings after grant
102,529 shares
Common Stock held directly by Ali Behbahani
Indirect holdings via NEA 16
4,448,757 shares
Common Stock held by New Enterprise Associates 16, L.P.
Key Terms
Sixth Amended and Restated Non-Employee Director Compensation Policy, pecuniary interest, Section 16 of the Securities Exchange Act of 1934, beneficial ownership
4 terms
Sixth Amended and Restated Non-Employee Director Compensation Policy financial
"These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy"
pecuniary interest financial
"the Reporting Person has no pecuniary interest"
Section 16 of the Securities Exchange Act of 1934 regulatory
"disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership within the meaning of Section 16"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What insider transaction did BDTX director Ali Behbahani report?
Ali Behbahani reported receiving a grant of 8,961 shares of Black Diamond Therapeutics common stock. The award was issued under the non-employee director compensation policy, reflecting his choice to take equity instead of cash for annual board service.
At what price was Ali Behbahani’s BDTX stock grant valued?
The 8,961-share grant to Ali Behbahani was valued using a price of $1.66 per share. This price was based on Black Diamond Therapeutics’ closing common stock price on June 18, 2026, as disclosed in the filing footnotes.
What indirect BDTX holdings are associated with Ali Behbahani?
The filing reports 4,448,757 Black Diamond Therapeutics shares indirectly held by New Enterprise Associates 16, L.P. Behbahani is a manager of related general partner entities but disclaims beneficial ownership of portions where he has no pecuniary interest.
AI-generated analysis. How Rhea-AI works. Not financial advice.
